Hans‐Georg Strauß

1.5k total citations
24 papers, 486 citations indexed

About

Hans‐Georg Strauß is a scholar working on Obstetrics and Gynecology, Epidemiology and Reproductive Medicine. According to data from OpenAlex, Hans‐Georg Strauß has authored 24 papers receiving a total of 486 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Obstetrics and Gynecology, 11 papers in Epidemiology and 11 papers in Reproductive Medicine. Recurrent topics in Hans‐Georg Strauß's work include Endometrial and Cervical Cancer Treatments (13 papers), Cervical Cancer and HPV Research (11 papers) and Ovarian cancer diagnosis and treatment (11 papers). Hans‐Georg Strauß is often cited by papers focused on Endometrial and Cervical Cancer Treatments (13 papers), Cervical Cancer and HPV Research (11 papers) and Ovarian cancer diagnosis and treatment (11 papers). Hans‐Georg Strauß collaborates with scholars based in Germany, Netherlands and Austria. Hans‐Georg Strauß's co-authors include Christoph Thomssen, Stefan Hüttelmaier, Martina Vetter, Sven� Mahner, Markus Glaß, Marcell Lederer, Danny Misiak, Nadine Bley, Simon Müller and Nikolaus de Gregorio and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Hans‐Georg Strauß

22 papers receiving 477 citations

Peers

Countries citing papers authored by Hans‐Georg Strauß

Since Specialization

Citations

This map shows the geographic impact of Hans‐Georg Strauß's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans‐Georg Strauß with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans‐Georg Strauß more than expected).

Fields of papers citing papers by Hans‐Georg Strauß

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans‐Georg Strauß. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans‐Georg Strauß. The network helps show where Hans‐Georg Strauß may publish in the future.

Co-authorship network of co-authors of Hans‐Georg Strauß

This figure shows the co-authorship network connecting the top 25 collaborators of Hans‐Georg Strauß. A scholar is included among the top collaborators of Hans‐Georg Strauß based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans‐Georg Strauß. Hans‐Georg Strauß is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Germline variants of homology‐directed repair or mismatch repair genes in cervical cancer 2024 ·International Journal of Cancer ·(unknown), Dhanya Ramachandran, Peter Schürmann, Robert Geffers, Matthias Jentschke, Gerd Böhmer, Hans‐Georg Strauß, (unknown), (unknown), Florian H. Müller, Peter A. Fasching, Alexander Luyten, Norman Häfner, (unknown), Thilo Dörk	1
2	Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ) 2023 ·Journal of Cancer Research and Clinical Oncology ·Radoslav Chekerov, (unknown), Klaus Pietzner, Ulrich Canzler, Pauline Wimberger, Hans‐Georg Strauß, Sven� Mahner, Linn Woelber, Nikolaus de Gregorio, (unknown), (unknown), Tanja Neunhoeffer, Antje Belau, Alexander Mustea, (unknown), Elena Ioana Braicu, Rolf Richter, Jalid Sehouli, (unknown)	2
3	Association of two genomic variants with HPV type-specific risk of cervical cancer 2023 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Julia Beckmann, Peter Schürmann, (unknown), Matthias Jentschke, Gerd Böhmer, Hans‐Georg Strauß, (unknown), (unknown), Florian H. Müller, Peter A. Fasching, Alexander Luyten, Norman Häfner, Matthias Dürst, Ingo B. Runnebaum, Peter Hillemanns, Thilo Dörk, Dhanya Ramachandran	1
4	Adjuvant radiotherapy and local recurrence in vulvar cancer – a subset analysis of the AGO-CaRE-1 study 2021 ·Gynecologic Oncology ·Linn Woelber, Katharina Prieske, Christine zu Eulenburg, Stefanie Corradini, Cordula Petersen, Mareike Bommert, Thomas Blankenstein, Felix Hilpert, Nikolaus de Gregorio, Séverine Iborra, Jalid Sehouli, Atanas Ignatov, Peter Hillemanns, Sophie Fuerst, Hans‐Georg Strauß, Klaus Baumann, Matthias W. Beckmann, Alexander Mustea, Sven� Mahner, Anna Jaeger	17
5	Role of Pelvic Lymph Node Resection in Vulvar Squamous Cell Cancer: A Subset Analysis of the AGO-CaRE-1 Study 2021 ·Annals of Surgical Oncology ·Linn Woelber, Mareike Bommert, Philipp Harter, Katharina Prieske, Christine zu Eulenburg, J Jueckstock, Felix Hilpert, Nikolaus de Gregorio, Séverine Iborra, Jalid Sehouli, Atanas Ignatov, Peter Hillemanns, Sophie Fuerst, Hans‐Georg Strauß, Klaus Baumann, Matthias Beckmann, Alexander Mustea, Werner Meier, Sven� Mahner, Anna Jaeger	2
6	Age, treatment and prognosis of patients with squamous cell vulvar cancer (VSCC) - analysis of the AGO-CaRE-1 study 2021 ·Gynecologic Oncology ·Katharina Prieske, Linn Woelber, Mustafa Zelal Muallem, Christine Eulenburg, J Jueckstock, Felix Hilpert, Nikolaus de Gregorio, Séverine Iborra, Atanas Ignatov, Peter Hillemanns, Sophie Fuerst, Hans‐Georg Strauß, Klaus Baumann, Matthias W. Beckmann, Alexander Mustea, Werner Meier, Philipp Harter, Pauline Wimberger, Jalid Sehouli, Sven� Mahner	11
7	IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer 2020 ·RNA Biology ·Nadine Bley, (unknown), Simon Müller, Danny Misiak, Marcell Lederer, Tommy Fuchs, (unknown), Markus Glaß, Christian Ihling, Andrea Sinz, Nikolaos Pazaitis, Claudia Wickenhauser, Martina Vetter, (unknown), Hans‐Georg Strauß, Christoph Thomssen, Stefan Hüttelmaier	29
8	Predicting the course of disease in recurrent vulvar cancer – A subset analysis of the AGO-CaRE-1 study 2019 ·Gynecologic Oncology ·Linn Woelber, Christine Eulenburg, (unknown), Petra Neuser, C Heiss, Peer Hantschmann, Peter Mallmann, Berno Tanner, Jacobus Pfisterer, Julia Jückstöck, Felix Hilpert, Nikolaus de Gregorio, Séverine Iborra, Jalid Sehouli, Atanas Ignatov, Peter Hillemanns, (unknown), Hans‐Georg Strauß, Sven� Mahner, Katharina Prieske	13
9	p53 and p16 expression profiles reveal three prognostically relevant subgroups in vulvar cancer: A TMA based study by the AGO-CaRE-translational study group. 2019 ·Journal of Clinical Oncology ·Linn Woelber, Katharina Prieske, Christine zu Eulenburg, Nikolaus de Gregorio, Rüdiger Klapdor, Matthias Kalder, Elena Ioana Braicu, Sophie Fuerst, (unknown), Hans‐Georg Strauß, Grit Mehlhorn, Werner Meier, Atanas Ignatov, Alexander Mustea, J Jueckstock, Georg Schmidt, Dirk Bauerschlag, Martin Hellriegel, Sven� Mahner, Eike Burandt	6
10	The oncogenic triangle of HMGA2, LIN28B and IGF2BP1 antagonizes tumor-suppressive actions of the let-7 family 2016 ·Nucleic Acids Research ·Bianca Busch, Nadine Bley, Simon Müller, Markus Glaß, Danny Misiak, Marcell Lederer, Martina Vetter, Hans‐Georg Strauß, Christoph Thomssen, Stefan Hüttelmaier	91
11	Prognosis after local recurrence in vulvar cancer: A subset analysis of the AGO-CaRE-1 study. 2016 ·Journal of Clinical Oncology ·Linn Woelber, Christine zu Eulenburg, (unknown), Petra Neuser, C Heiss, Peer Hantschmann, Peter Mallmann, Berno Tanner, Jacobus Pfisterer, Barbara Richter, J Jueckstock, Felix Hilpert, Nikolaus de Gregorio, Séverine Iborra, Jalid Sehouli, (unknown), Peter Hillemanns, Sophie Fuerst, Hans‐Georg Strauß, Sven� Mahner	0
12	Adjuvant Therapy in Lymph Node–Positive Vulvar Cancer: The AGO-CaRE-1 Study 2015 ·JNCI Journal of the National Cancer Institute ·Sven� Mahner, J Jueckstock, Felix Hilpert, Petra Neuser, Philipp Harter, Nikolaus de Gregorio, Annette Hasenburg, Jalid Sehouli, (unknown), Peter Hillemanns, Sophie Fuerst, Hans‐Georg Strauß, Klaus Baumann, Falk C. Thiel, Alexander Mustea, Werner Meier, Andreas du Bois, L. Griebel, Linn Woelber	128
13	Quality of life and sexual function in patients with borderline tumors of the ovary. A substudy of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group ROBOT study 2014 ·Supportive Care in Cancer ·Juliane Farthmann, Annette Hasenburg, (unknown), Christina Fotopoulou, Nina Ewald-Riegler, (unknown), Fabian Trillsch, Sven� Mahner, Hans‐Georg Strauß, Pauline Wimberger, Alexander Reuß, Andreas du Bois	7
14	Phase II study of fulvestrant 250mg/month in patients with recurrent or metastatic endometrial cancer: A study of the Arbeitsgemeinschaft Gynäkologische Onkologie 2013 ·Gynecologic Oncology ·Günter Emons, Andreas R. Günthert, Falk C. Thiel, Oumar Camara, Hans‐Georg Strauß, G. P. Breitbach, H. Kölbl, Toralf Reimer, D. Finas, (unknown)	31
15	Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabin plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): A randomized phase III trial of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG intergroup study (HECTOR). 2012 ·Journal of Clinical Oncology ·Jalid Sehouli, Werner Meier, Pauline Wimberger, Radoslav Chekerov, Antje Belau, Sven� Mahner, Christian Kurzeder, Felix Hilpert, Peter Klare, (unknown), Hans‐Georg Strauß, Ulrich Canzler, Christian Marth, Alexander Reinthaller, Edgar Petru, Rolf Richter, María Jesús Rubio, Isabel Bover, Antonio González-Martı́n, Philipp Harter	6
16	Impact of adjuvant therapy in lymph-node positive vulvar cancer: The AGO CARE 1 study. 2012 ·Journal of Clinical Oncology ·Sven� Mahner, J Jueckstock, Felix Hilpert, (unknown), Philipp Harter, Nikolaus de Gregorio, Séverine Iborra, Frank Chen, (unknown), Peter Hillemanns, Sophie Fuerst, Hans‐Georg Strauß, Klaus Baumann, Falk C. Thiel, Alexander Mustea, Werner Meier, Andreas du Bois, Pauline Wimberger, L. Griebel, Linn Woelber, (unknown)	4
17	Phase 2 Trial of Docetaxel, Gemcitabine, and Oxaliplatin Combination Chemotherapy in Platinum- and Paclitaxel-Pretreated Epithelial Ovarian Cancer 2009 ·International Journal of Gynecological Cancer ·G Seliger, Lutz Peter Mueller, Thomas Kegel, Eva Johanna Kantelhardt, Axel Grothey, (unknown), Hans‐Georg Strauß, Heinz Koelbl, Christoph Thomssen, Hans‐Joachim Schmoll	12
18	Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer 2008 ·Anti-Cancer Drugs ·Hans‐Georg Strauß, (unknown), (unknown), Christine Lautenschläger, (unknown), Christoph Thomssen	18
19	Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas 2006 ·Modern Pathology ·Martin Köbel, (unknown), Stefan Hüttelmaier, Wolfgang Schmitt, (unknown), Jürgen Dittmer, Hans‐Georg Strauß, Christoph Thomssen, Steffen Hauptmann	55
20	Chemoradiation in Cervical Cancer with Cisplatin and High-Dose Rate Brachytherapy Combined with External Beam Radiotherapy 2002 ·Strahlentherapie und Onkologie ·Hans‐Georg Strauß, Thomas Kuhnt, (unknown), (unknown), Steffi Pigorsch, Juergen Dunst, Heinz Koelbl, G. Haensgen	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact